March 22, 2021 – Edge Pharma, an FDA registered 503B Outsourcing Facility, has entered into an agreement with Capstone Health Alliance (Fletcher, NC) to provide Capstone’s 300 member hospitals with Edge’s unit-dose repackaged Mvasi (Bevicizumab-awwb) syringes.
The agreement, effective March 1, 2021, designates Edge as a supplier for repackaged Mvasi (Bevicizumab-awwb) syringes to Capstone hospitals, where it will be considered a “preferred” product.
Mvasi is one of two FDA-approved Avastin biosimilars.
The FDA recognizes biosimilars and stipulates that biosimilars must be expected to produce the same clinical result as the original biologic, which is referred to as the reference product. Biosimilars must be able to be alternated with the reference product without increasing risk to the patient.
Edge Pharma repackages Mvasi into unit-dose, silicone-free syringes. Every batch of repackaged Mvsai from Edge Pharma undergoes rigorous sterility, potency, endotoxin, visual inspection, and subvisible particle analysis before release.
Capstone Health Alliance is a group purchasing alliance of healthcare and non-healthcare members that delivers cost savings through the power of aggregation and collaboration. Capstone’s membership includes 300 Hospitals representing more than 140 Health Systems across 23 states and represents over $10 billion in acute care supply chain spend. In addition to cost savings initiatives, Capstone members collaborate to share best practices all with the intent of improving cost, quality, and outcomes.